Creative Capital Management Investments’s Denali Therapeutics DNLI Stock Holding History

Creative Capital Management Investments’s Portfolio DNLI Stock Details DNLI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$463	Buy	+18	New	+$370	﹤0.01%	1285

Other funds holding DNLI

T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Temasek Holdings Singapore $37.3B AUM 12.6% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Creative Capital Management Investments's DNLI Position: Q2 2026 in Review

Creative Capital Management Investments opened a new position in Denali Therapeutics (DNLI) in Q2 2026: 18 shares worth $463. The stake represents ﹤0.01% of the portfolio and ranks #1285 among its holdings.

294 funds tracked by Wall St. Rank hold DNLI as of Q2 2026.

Creative Capital Management Investments held 18 shares of Denali Therapeutics worth $463 as of Q2 2026.
Denali Therapeutics was a new Creative Capital Management Investments position in Q2 2026.
Denali Therapeutics made up ﹤0.01% of Creative Capital Management Investments's portfolio in Q2 2026, its #1285 holding.
294 funds tracked by Wall St. Rank held Denali Therapeutics as of Q2 2026.

Based on Creative Capital Management Investments's 13F filing for Q2 2026, filed 24 Jul 2026.